Michael J Birrer

Summary

Affiliation: National Institutes of Health
Country: USA

Publications

  1. ncbi request reprint Ovarian cancer: not a borderline issue!
    Michael J Birrer
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 5:786-7. 2006
  2. ncbi request reprint Summary and discussion of session recommendations
    Jane Fountain
    National Cancer Institute, Bethesda, MD 20892, USA
    Gynecol Oncol 103:S23-5. 2006
  3. ncbi request reprint Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas
    Michael J Birrer
    Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 25:2281-7. 2007
  4. ncbi request reprint Etiology and pathogenesis of epithelial ovarian cancer
    Samuel C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Dis Markers 23:367-76. 2007
  5. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
  6. ncbi request reprint The future of phase II trials
    John Farley
    Division of Gynecologic Oncology, Tripler Army Medical Center, 1 Jarrett White Road, TAMC 96859 5000, USA
    Gynecol Oncol 103:S20-2. 2006
  7. ncbi request reprint Biomarker discovery in epithelial ovarian cancer by genomic approaches
    Samuel C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Adv Cancer Res 96:1-22. 2007
  8. ncbi request reprint Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma
    Chunhua Lu
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:1757-68. 2007
  9. ncbi request reprint Biomarkers of mucinous tumors of the ovary
    Goli Samimi
    Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892, USA
    Dis Markers 23:389-96. 2007
  10. ncbi request reprint Cell cycle and related protein
    John Farley
    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Dis Markers 23:433-43. 2007

Collaborators

Detail Information

Publications34

  1. ncbi request reprint Ovarian cancer: not a borderline issue!
    Michael J Birrer
    National Institutes of Health, Bethesda, Maryland 20892, USA
    Cancer Biol Ther 5:786-7. 2006
  2. ncbi request reprint Summary and discussion of session recommendations
    Jane Fountain
    National Cancer Institute, Bethesda, MD 20892, USA
    Gynecol Oncol 103:S23-5. 2006
  3. ncbi request reprint Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas
    Michael J Birrer
    Cell and Cancer Biology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
    J Clin Oncol 25:2281-7. 2007
    ..To identify markers that can predict overall survival in patients with high-grade advanced stage serous adenocarcinomas...
  4. ncbi request reprint Etiology and pathogenesis of epithelial ovarian cancer
    Samuel C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Dis Markers 23:367-76. 2007
    ..However, the link between all these genetic changes and the etiological factors remains to be established...
  5. ncbi request reprint Workshop on imaging science development for cancer prevention and preemption
    Gary J Kelloff
    NIH NCI DCTD, Cancer Imaging Program, Bethesda, MD, USA
    Cancer Biomark 3:1-33. 2007
    ..Imaging devices, alone or in combination with anticancer drugs, may also provide novel interventions to treat or prevent precancer...
  6. ncbi request reprint The future of phase II trials
    John Farley
    Division of Gynecologic Oncology, Tripler Army Medical Center, 1 Jarrett White Road, TAMC 96859 5000, USA
    Gynecol Oncol 103:S20-2. 2006
  7. ncbi request reprint Biomarker discovery in epithelial ovarian cancer by genomic approaches
    Samuel C Mok
    Department of Obstetrics, Gynecology, and Reproductive Biology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Adv Cancer Res 96:1-22. 2007
    ..These powerful techniques hold the potential to unravel the genetic origins of ovarian cancer. Hopefully, this will translate into earlier diagnosis and better patient outcome from disease...
  8. ncbi request reprint Gene alterations identified by expression profiling in tumor-associated endothelial cells from invasive ovarian carcinoma
    Chunhua Lu
    Departments of Gynecologic Oncology and Cancer Biology, University of Texas M D Anderson Cancer Center, Houston, TX 77030, USA
    Cancer Res 67:1757-68. 2007
    ..The present study shows that tumor and normal endothelium differ at the molecular level, which may have significant implications for the development of antiangiogenic therapies...
  9. ncbi request reprint Biomarkers of mucinous tumors of the ovary
    Goli Samimi
    Cancer Prevention Fellowship Program, National Cancer Institute, Bethesda, MD 20892, USA
    Dis Markers 23:389-96. 2007
  10. ncbi request reprint Cell cycle and related protein
    John Farley
    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Dis Markers 23:433-43. 2007
  11. doi request reprint Early events in the pathogenesis of epithelial ovarian cancer
    Charles N Landen
    Department of Gynecologic Oncology, University of Texas M D Anderson Cancer Center, 1155 Herman Pressler, Unit 1362, Houston, TX 77030, USA
    J Clin Oncol 26:995-1005. 2008
    ....
  12. doi request reprint Overexpression of CEACAM6 in borderline and invasive mucinous ovarian neoplasms
    Behrang Litkouhi
    Robert Wood Johnson Medical School, University of Medicine and Dentistry of New Jersey, Piscataway, NJ, USA
    Gynecol Oncol 109:234-9. 2008
    ..Microarray analysis previously demonstrated high CEACAM6 overexpression in MON's and this study sought to validate this finding...
  13. doi request reprint Genomic analysis of epithelial ovarian cancer
    John Farley
    Department of Obstetrics and Gynecology, Uniformed Services University of Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Cell Res 18:538-48. 2008
    ..This review summarizes the new genomic data on epithelial ovarian cancers of different histology and grade and the impact it will have on our understanding and treatment of this disease...
  14. pmc Genomic and epigenetic alterations deregulate microRNA expression in human epithelial ovarian cancer
    Lin Zhang
    Center for Research on Early Detection and Cure of Ovarian Cancer and Gynecology, Department of Obstetrics, University of Pennsylvania, Philadelphia, PA 19104, USA
    Proc Natl Acad Sci U S A 105:7004-9. 2008
    ..Therefore, our results suggest that miRNAs may offer new biomarkers and therapeutic targets in epithelial ovarian cancer...
  15. doi request reprint Classification of ovarian cancer: a genomic analysis
    Michael P Stany
    Adv Exp Med Biol 622:23-33. 2008
  16. doi request reprint A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer
    Tomas Bonome
    Cell and Cancer Biology Branch, National Cancer Institute, NIH, Rockville, Maryland 20892, USA
    Cancer Res 68:5478-86. 2008
    ..Ultimately, the prognostic classifier defined for suboptimally debulked tumors may aid in the classification and enhancement of patient outcome for this high-risk population...
  17. ncbi request reprint Biomarkers and clinical trial design
    John Farley
    Department of Obstetrics and Gynecology, Uniformed Services University of the Health Sciences, 4301 Jones Bridge Road, Bethesda, MD 20814, USA
    Gynecol Oncol 103:S3-5. 2006
  18. ncbi request reprint CL100 expression is down-regulated in advanced epithelial ovarian cancer and its re-expression decreases its malignant potential
    Ramon G Manzano
    Cell and Cancer Biology Department, National Cancer Institute, 9610 Medical Center Drive, Rockville, Maryland 20850, USA
    Oncogene 21:4435-47. 2002
    ..These data suggest that down-regulation of CL100 may play a role in the progression of human ovarian cancer...
  19. ncbi request reprint Expression profiling identifies altered expression of genes that contribute to the inhibition of transforming growth factor-beta signaling in ovarian cancer
    Jan S Sunde
    Walter Reed Army Medical Center, Washington, District of Columbia, USA
    Cancer Res 66:8404-12. 2006
    ..These results suggest that altered expression of these genes is responsible for disrupted TGF-beta signaling in ovarian cancer and they may be useful as new and novel therapeutic targets for ovarian cancer...
  20. ncbi request reprint Cyclin E expression is a significant predictor of survival in advanced, suboptimally debulked ovarian epithelial cancers: a Gynecologic Oncology Group study
    John Farley
    Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Tripler Army Medical Center TAMC, HI, 96859 5000, USA
    Cancer Res 63:1235-41. 2003
    ..006). High cyclin E expression was an independent poor prognostic factor for patients with advanced ovarian cancer, and it was associated with amplification of the cyclin E gene...
  21. ncbi request reprint Choice of normal ovarian control influences determination of differentially expressed genes in ovarian cancer expression profiling studies
    Kristin K Zorn
    Department of Cell and Cancer Biology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland 20850, USA
    Clin Cancer Res 9:4811-8. 2003
    ..Our purpose was to assess the impact of the use of different types of normal controls on the determination of gene expression alterations in ovarian cancer studies...
  22. ncbi request reprint Synthesis of flexible sulfur-containing heteroarotinoids that induce apoptosis and reactive oxygen species with discrimination between malignant and benign cells
    Shengquan Liu
    Department of Chemistry, Oklahoma State University, Stillwater, Oklahoma 74078 3071, USA
    J Med Chem 47:999-1007. 2004
    ..The growth inhibition was associated with cell loss and induction of reactive oxygen species...
  23. ncbi request reprint Current challenges and opportunities for research on borderline ovarian tumors
    Mark E Sherman
    Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, MD 20892, USA
    Hum Pathol 35:961-70. 2004
    ....
  24. ncbi request reprint Whole genome expression profiling of advance stage papillary serous ovarian cancer reveals activated pathways
    Howard Donninger
    Department of Cell and Cancer Biology, National Cancer Institute, Rockville, MD 20850, USA
    Oncogene 23:8065-77. 2004
    ....
  25. ncbi request reprint Cyclin E amplification and overexpression in clear cell adenocarcinoma of the ovary
    Hiroshi Tsuda
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, MA 02115, USA
    Oncology 67:291-9. 2004
    ..The purpose of this study is to compare DNA, mRNA and protein levels of the cyclin E between clear cell (CC) and serous (SC) ovarian carcinomas, and evaluate the relationship between cyclin E and p53 status...
  26. ncbi request reprint Identification of DNA copy number changes in microdissected serous ovarian cancer tissue using a cDNA microarray platform
    Hiroshi Tsuda
    Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Dana Farber Cancer Institute, Harvard Medical School, BLI 447, 221 Longwood Avenue, Boston, MA 02115, USA
    Cancer Genet Cytogenet 155:97-107. 2004
    ..These results show the feasibility of using the cDNA array platform to identify changes in DNA and mRNA copy number simultaneously in microdissected tumor tissues...
  27. pmc p75-Ras-GRF1 is a c-Jun/AP-1 target protein: its up regulation results in increased Ras activity and is necessary for c-Jun-induced nonadherent growth of Rat1a cells
    Virna D Leaner
    National Cancer Institute, 9610 Medical Center Dr, Room 300, Rockville, MD 20850 3300, USA
    Mol Cell Biol 25:3324-37. 2005
    ..We conclude that c-Jun/AP-1 regulates endogenous p75-Ras-GRF1 expression and that c-Jun/AP-1-regulated anchorage-independent cell growth requires activation of Ras-PI3K-AKT signal transduction...
  28. ncbi request reprint Gene expression profiles associated with response to chemotherapy in epithelial ovarian cancers
    Amir A Jazaeri
    Laboratory of Biosystems and Cancer, Center for Cancer Research, National Cancer Institute, Bethesda, Maryland, USA
    Clin Cancer Res 11:6300-10. 2005
    ..The goal of this study was to determine whether distinct gene expression profiles are associated with intrinsic and/or acquired chemoresistance in epithelial ovarian carcinoma...
  29. ncbi request reprint Gene expression profiles of serous, endometrioid, and clear cell subtypes of ovarian and endometrial cancer
    Kristin K Zorn
    National Cancer Institute, Bethesda, MD 20892, USA
    Clin Cancer Res 11:6422-30. 2005
    ..This study compares the gene expression profiles of analogous histologic subtypes of cancers of the ovary and endometrium using the same genomic platform to determine the similarities and differences between these tumors...
  30. ncbi request reprint Identification of overexpression and amplification of ABCF2 in clear cell ovarian adenocarcinomas by cDNA microarray analyses
    Hiroshi Tsuda
    Department of Obstetrics and Gynecology, Laboratory of Gynecologic Oncology, Brigham and Women s Hospital, Harvard Medical School, Boston, Massachusetts 02115, USA
    Clin Cancer Res 11:6880-8. 2005
    ..Genetic changes in this group of cancer have not been thoroughly explored. Identification of these changes may provide us new therapeutic targets to treat this disease...
  31. ncbi request reprint Expression profiling of serous low malignant potential, low-grade, and high-grade tumors of the ovary
    Tomas Bonome
    Cell and Cancer Biology Branch, National Cancer Institute, Bethesda, Maryland 20892, USA
    Cancer Res 65:10602-12. 2005
    ..Prominent expression of p53 pathway members may play an important role in the LMP tumor phenotype...
  32. ncbi request reprint Expression profiling of mucinous tumors of the ovary identifies genes of clinicopathologic importance
    Fred W Wamunyokoli
    Cell and Cancer Biology Branch, National Cancer Institute, NIH, Bethesda, Maryland 20892, USA
    Clin Cancer Res 12:690-700. 2006
    ..To elucidate the molecular mechanisms contributing to the unique clinicopathologic characteristics of mucinous ovarian carcinoma, global gene expression profiling of mucinous ovarian tumors was carried out...
  33. ncbi request reprint Roles of KLF6 and KLF6-SV1 in ovarian cancer progression and intraperitoneal dissemination
    Analisa Difeo
    Department of Human Genetics, Mount Sinai School of Medicine, 1425 Madison Avenue, New York, New York 10029, USA
    Clin Cancer Res 12:3730-9. 2006
    ..We investigated the role of the KLF6 tumor suppressor gene and its alternatively spliced isoform KLF6-SV1 in epithelial ovarian cancer (EOC)...
  34. doi request reprint Asparagine synthetase is a predictive biomarker of L-asparaginase activity in ovarian cancer cell lines
    Philip L Lorenzi
    Genomics and Bioinformatics Group, Laboratory of Molecular Pharmacology, Center for Cancer Research, National Cancer Institute, NIH, Bethesda, Maryland, USA
    Mol Cancer Ther 7:3123-8. 2008
    ..These findings provide rationale for evaluation of ASNS protein expression as a predictive biomarker of clinical L-ASP activity in ovarian cancer...